Department of Orthopedics, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China.
Department of Anesthesiology, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China.
Medicine (Baltimore). 2024 Nov 29;103(48):e40742. doi: 10.1097/MD.0000000000040742.
Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by axial osteoarticular inflammation and tendon enthesitis with unclear pathogenesis. Nonsteroidal anti-inflammatory drugs and antirheumatic drugs used in the traditional treatment of AS have some problems such as drug intolerance and inadequate treatment response. Since the introduction of biological agents in the treatment of AS, they have completely changed the treatment concept of AS, and because of their safety and good tolerance, they have become the main choice for clinical AS patients. This article systematically summarizes the current status of targeted therapy for AS worldwide, analyzes the advantages and disadvantages of different types of biological agents in the treatment of AS, and provides an objective evaluation of clinical targeted therapy for AS, in order to provide a new perspective for clinical standardized treatment.
强直性脊柱炎（AS）是一种慢性炎症性疾病，以中轴骨关节炎症和肌腱附着点炎为特征，其发病机制尚不清楚。传统治疗 AS 的非甾体抗炎药和抗风湿药存在药物不耐受和治疗反应不足等问题。自生物制剂用于治疗 AS 以来，它们彻底改变了 AS 的治疗理念，并且由于其安全性和良好的耐受性，它们已成为临床 AS 患者的主要选择。本文系统总结了目前全球 AS 的靶向治疗现状，分析了不同类型生物制剂治疗 AS 的优缺点，对 AS 的临床靶向治疗进行了客观评价，以期为临床规范化治疗提供新视角。
